What You Need to Know about CMS and Clinical Trials
Why clinical trials are a crucial element in the path toward better treatment for Congenital Myasthenic Syndromes.
What Is Congenital Myasthenic Syndrome (CMS)?
Congenital Myasthenic Syndrome (CMS) is a rare genetic condition caused by defective genes that affect the receptors at the neuromuscular junction (NMJ), where the nerves connect to the muscles. The interference at the NMJ, the point where the nerves signal the muscles to contract, results in muscle weakness that can affect the eyes, and the limbs, as well as chewing and swallowing.
“Blood tests with genetic typing establish the diagnosis of CMS, but it’s important to know which of the gene mutations are the cause of it. ”
There are many faulty genes known to be associated with CMS, such as CHRNA, CHRNB, CHRND, CHRNE, CHAT, COLQ, RAPSN and MUSK, ChAT, COLQ, rapsyn, LRP4 and DOK7. Those with ChAT and COLQ usually show symptoms at birth or early infancy. Blood tests with genetic typing establish the diagnosis of CMS, but it’s important to know which of the gene mutations are the cause of it. The gene mutation can determine the age it becomes evident, the course of the disease, and the response to treatments. It seems that the more common gene mutations are DOK7 and rapsyn, but there are no extensive studies that establish that perception.
How Is CMS Diagnosed?
CMS can be difficult to diagnose because its symptoms resemble so many other diseases. Surveys have shown that up to 80% of young children with CMS are misdiagnosed, while 94% of adults are misdiagnosed. The most common symptoms are droopy eyelids and facial muscles, especially in the first decade of life. In adults, CMS often causes weakness of the limbs and leads to misdiagnosis of autoimmune diseases like myasthenia gravis (MG).
Because CMS due to DOK7 mutations is a rare disorder, and difficult to diagnose, there have not been enough participants to fuel clinical trials investigating potential new treatments. Therefore, much of what is known about treating CMS derives from small studies from specific hospitals or clinics. From one such study center in Oxford, UK, adults diagnosed with DOK7 CMS, where signs and symptoms were first noticed under age 10, responded to treatment with pyridostigmine.
More information was gathered on the symptoms of and treatments for people diagnosed with DOK7 CMS from another small study, which surveyed 10 adults diagnosed with DOK7 CMS. This study found that although their symptoms might have been worse as children, they then stabilized for a time before becoming progressively worse. These people were able to manage their symptoms with ephedrine, but the response seemed to be better over time rather than immediately.
“As of now, there are not many large studies about the experiences of those who have been diagnosed with CMS.”
Why are Clinical Studies About CMS so Important?
Unfortunately, as of now, there are not many large studies or established research about the experiences of those who have been diagnosed with CMS—particularly people who may not have received a confirmed diagnosis or underwent their specific mutation as adults. As is the case with myasthenia gravis, neuromyelitis optica spectrum disease, or MOGAD antibody disease, more about CMS can be discovered via research studies, particularly observational studies. These studies can provide more insight into the initial characteristics of the disease as well as its progression, and as a result, new therapies can be developed. It is up to us to participate in studies that can shed light on the experiences of those living with rare diseases so that additional studies can be designed that reflect the reality of the human experience.
Sources:
Jagtap, et al. ‘Congenital myasthenia syndromes’, Ann Indian Acad of Neurol, 2013; 16: 3, pp.338-341.
Lashley D, et al. Neurology 2010;74:1517–1523.
Palace J, et al. Brain (2007), 130, 1507-1515.
Latest From Know Rare
From prenatal uncertainty and postpartum anxiety to therapy, grief, and hope, a mother shares her experience raising a child with a rare disease, navigating the healthcare system, finding community, and learning to embrace a different—but deeply meaningful—path as a parent.
A Danon disease study, led by researcher Dr. Barry Greenberg and published in the New England Journal of Medicine, wins an award! The study focuses on gene therapy as a potential treatment option for Danon disease. The study showed early signs that gene therapy may help the hearts of people with Danon disease.
A poster, presented at the European Hematology Association meeting in June, described a study that looked at tiredness (fatigue) in adults with immune thrombocytopenia (ITP). Researchers wanted to see if fatigue was related to bleeding or other health test results.
Lucky Shanmugan was recently featured in Porter Ranch Living, his local magazine, for Father’s Day: in his interview, Lucky talks about Osteogenesis Imperfecta, a rare genetic or heritable disorder of the connective tissue, and the incredible journey towards his official diagnosis.
Here are 9 things Chris Anselmo wishes someone had told him after his rare disease diagnosis.
A family’s hardships and resilience in finding answers and getting a diagnosis for their child, after numerous tests, brain biopsies, and hospitalizations. And the relief but also grief in finally putting a name to the rare disease that affects their child: BCL11B-related disorder.
The Danon Foundation boldly empowers people living with Danon disease, providing trusted information, resources and support to help navigate life, from diagnosis to treatment.
For many families, caregiving for a child with a rare or medically complex condition is a full-time job. The problem is, it’s a job with no training, no time off, and no clear job description. If you’re looking for the light at the end of the tunnel, you don’t have to search alone. Check out some of Paige’s favorite resources.
For most of celiacs, despite months on a strict GF diet, energy stays low and blood work reveals nutrient deficiencies. The lesson? A "gluten-free" label isn't a health guarantee—just a guarantee you'll pay more.
If you’ve been told you have seronegative NMOSD, there’s nearly 50/50 chance you have a different antibody causing your symptoms –MOG antibody.
Therapy Near Me is a nationwide mental health service based in Australia, providing easy access to psychologists, counsellors, behaviour support practitioners and social workers.
At the annual Kidney Week of the American Society of Nephrologists (ASN), the world’s largest kidney healthcare professional organization, new advances in research were highlighted. Over $35 million has been invested in research with the ASN, and there are many treatments in development for IgA Nephropathy (IgAN), with researchers actively investigating more than 20 different drugs.
When I was diagnosed with celiac disease, I thought avoiding bread and pasta would be enough. I quickly learned that living truly gluten-free is far more complex, and I'm sharing my experience to help newly diagnosed individuals understand what lies ahead.
Retinopathy is an eye problem that many people with Danon disease have. It can cause dark spots in the outer part of the eye, blurry or worse vision, and unusual test results on an eye exam. Sometimes these eye changes show up before heart problems, so an eye check can help find the disease early.
A heartfelt story about a mother who found purpose and strength among the tragedy of losing a child diagnosed with an ultra rare genetic disorder.
Kaya Girl Legacy, Inc. is a Florida-based nonprofit founded in memory of Kaya Humbert, a beautiful baby girl born with Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS), one of 46 known cases worldwide. The foundation is dedicated to empowering families with knowledge about their genetic health and advocating for early access to genetic testing and rare disease awareness.
A prose poem by Jim Kuhn, a rare warrior living with Sarcoidosis, a rare inflammatory disease.
Rare Mom Laura shares how her family’s prep for Halloween turned into a burst of familial love and creativity, as they all worked together in designing and building a costume for Alden, her medically complex son.
Instead of starting with a newly discovered drug compound, PCOR is a type of research that starts by turning to patients and caregivers and asking, What matters most to you? What questions do we want answered? What symptoms do we wish were better managed? What keeps us up at night?
Four years ago, Michael Grivas’ life suddenly changed when he learned that he had Brugada Syndrome, a genetic disorder in which the electrical activity of the heart is abnormal due to channelopathy. Learn more about his story.
Fatigue is a very common and often debilitating symptom of IgAN. It is linked to disease progression and reduced kidney function, but other factors like inflammation, anemia, and mental health also play a role. In a 2025 study, the majority of patients with IgAN reported fatigue, and patients with more severe proteinuria and lower kidney filtration rates (eGFR) experienced worse fatigue.
Why is it so hard to accept help? Humans often associate help with weakness and loss of independence and control. However, if we reframe our thoughts, accepting help can be viewed as a form of empowerment: showing vulnerability and trusting someone to help us requires great strength.
There is so much mental load with having a rare disease. Rare Human Lindsay shares there are things she does not care about anymore, as she manages rare disease symptoms, specialists, and clinical trials.
Rare Human Lindsay shares her "silver linings." It's not 'what doesn't kill you makes you stronger,' instead it's what doesn't kill you makes you braver. She shares that she has found deeper connections with others, improved her ability to ask for and accept help, and not been as afraid of the word "no."
Journalist and rare disease advocate Lindsay Guentzel breaks down why clinical trials are a lifeline for the rare disease community. With only 5% of known rare diseases having an FDA-approved therapy, trials often represent the only path toward treatment, progress, and hope.
Lindsay was diagnosed with dermatomyositis a couple of years ago. Since then, she has undergone more than 350 doctor appointments, 250+ hours of infusions, 10+ ER visits, while juggling insurance approvals, rides, and her pain and fatigue.
Rare Human Lindsay is in the midst of her first clinical trial for dermatomyositis, a rare inflammatory disease that primarily affects the skin and muscles. So far, she has learned so much about the process and is eager to share some of her insights with the rare disease community.